FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 2 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab March 4, 2021 Genetic Signature May Help Tailor Treatment for Meningioma December 21, 2023 Reflections from our chief scientist: The rise of the whole organism February 4, 2022 Study Links Mental Health Treatment to Improved Cancer Survival July 10, 2020 Load more HOT NEWS After a Breast Cancer Diagnosis, Men May Be More Likely to... Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations A Diagnosis of Advanced Lung Cancer Is Not a Death Sentence Educators Raise Money in Memory of Teacher Who Dedicated Herself to...
